Email updates

Keep up to date with the latest news and content from Proteome Science and BioMed Central.

Open Access Highly Accessed Open Badges Research

Plasma and urine biomarkers in acute viral hepatitis E

Shikha Taneja1, Somdutta Sen2, Vijay K Gupta3, Rakesh Aggarwal4 and Shahid Jameel1*

Author Affiliations

1 Virology Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi - 110067, India

2 The Centre for genomic Applications, Okhla Industrial Area (Phase III), New Delhi - 110020, India

3 Department of Gastroenterology, Army Hospital, Delhi Cantonment, New Delhi - 110010, India

4 Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute for Medical Sciences, Rae Bareilly Road, Lucknow - 226014, India

For all author emails, please log on.

Proteome Science 2009, 7:39  doi:10.1186/1477-5956-7-39

Published: 27 October 2009



Hepatitis E, caused by the hepatitis E virus (HEV), is endemic to developing countries where it manifests as waterborne outbreaks and sporadic cases. Though generally self-limited with a low mortality rate, some cases progress to fulminant hepatic failure (FHF) with high mortality. With no identified predictive or diagnostic markers, the events leading to disease exacerbation are not known. Our aim is to use proteomic tools to identify biomarkers of acute and fulminant hepatitis E.


We analyzed proteins in the plasma and urine of hepatitis E patients and healthy controls by two-dimensional Differential Imaging Gel Electrophoresis (DIGE) and mass spectrometry, and identified over 30 proteins to be differentially expressed during acute hepatitis E. The levels of one plasma protein, transthyretin, and one urine protein, alpha-1-microglobulin (α1m), were then quantitated by enzyme immunoassay (EIA) in clinical samples from a larger group of patients and controls. The results showed decreased plasma transthyretin levels (p < 0.005) and increased urine α1m levels (p < 0.001) in acute hepatitis E patients, compared to healthy controls. Preliminary results also showed lower urine zinc alpha glycoprotein levels in fulminant hepatitis E compared to acute disease; this remains to be confirmed with more fulminant cases.


Our results demonstrate the utility of characterizing plasma and urine proteomes for signatures of the host response to HEV infection. We predict that plasma transthyretin and urine α1m could be reliable biomarkers of acute hepatitis E. Besides the utility of this approach to biomarker discovery, proteome-level changes in human biofluids would also guide towards a better understanding of host-virus interaction and disease.